Additional Considerations to Help Manage the Anti-VEGF Injection Burden during the COVID-19 Pandemic

April 4, 2020

Background

At the Association of Canadian University Professor of Ophthalmology (ACUPO) teleconference on March 24, 2020, Canadian Department Heads were interested in developing recommendations to assist balancing crucial reductions in anti-VEGF treatment volumes, driven by the COVID-19 virus, with essential treatments still needed for sight preservation. Following a literature review focusing on randomized clinical trials, the following recommendations were developed. Subsequently, the document was reviewed by ACUPO and the Canadian Ophthalmological Society (COS) for feedback.

This document Additional Considerations to Help Manage the Anti-VEGF Injection Burden during the COVID-19 Pandemic is supplementary to and expands on the foundational CRS March 19, 2020 Canadian Retina Society (CRS) Position Statement on Intravitreal Injections and the Management of Retinal Diseases during the COVID-19 Crisis. Both documents can be found on the COS Practice Resource Center. The data and suggestions that follow, as always, do not replace appropriate clinical judgement; clinicians will need to consider the specifics of each patient’s unique ocular and systemic health status and provide care that is in the patient’s best interest.  

Access Details

Read the full statement for the Additional Considerations to Help Manage the Anti-VEGF Injection Burden during the COVID-19 Pandemic.